SAN DIEGO--(BUSINESS WIRE)--MediPrint Ophthalmics, a clinical stage ophthalmic company focused on transforming the delivery of ophthalmic pharmaceuticals, today proudly announced the appointment of Thomas Bender as a strategic advisor. Mr. Bender, former President, CEO, and Chairman of CooperVision and The Cooper Companies, will lend his vast expertise to the company’s management and board of directors in developing its proprietary technology for delivery of ophthalmic drugs via contact lenses..

圣地亚哥——（商业新闻短讯）——MediPrint Ophthalmics是一家临床阶段的眼科公司，专注于改变眼科药物的交付方式，今天骄傲地宣布任命托马斯·本德为战略顾问。Bender先生是CooperVision和Cooper公司的前总裁、首席执行官兼董事长，他将为公司管理层和董事会提供丰富的专业知识，以开发通过隐形眼镜输送眼科药物的专有技术。。

Mr. Praful Doshi, CEO and Founder of MediPrint Ophthalmics, welcomed the new addition, stating, 'Tom Bender's appointment marks a defining moment for our company. His exceptional leadership transformed CooperVision into a global market leader, and we anticipate his insights will greatly progress our strategic initiatives and operational excellence.'.

MediPrint Ophthalmics首席执行官兼创始人Praful Doshi先生对这一新加入表示欢迎，他说：“汤姆·本德的任命标志着我们公司的决定性时刻。他卓越的领导才能将CooperVision转变为全球市场领导者，我们预计他的见解将极大地推动我们的战略举措和卓越运营。”。

Mr. Bender served as CEO of CooperVision from 1991 until his retirement as CEO in 2007, continuing as Chairman until 2021. Under Mr. Bender’s leadership, CooperVision grew from a $20 million operation to a multi-billion-dollar leader in the contact lens industry. Prior to his tenure at CooperVision, Mr.

Bender先生从1991年起担任CooperVision的首席执行官，直到2007年退休担任首席执行官，一直担任董事长，直到2021年。在本德先生的领导下，CooperVision从2000万美元的业务发展成为隐形眼镜行业数十亿美元的领导者。在任职CooperVision之前。

Bender was an executive at Allergan for 25 years, leading up to his role as President of Herbert Labs from 1986 to 1991..

Bender在Allergan担任了25年的高管，从1986年到1991年，他担任了Herbert Labs的总裁。。

Mr. Bender’s joining of MediPrint Ophthalmics is timely as the company advances its leading product in delivery of Glaucoma medication to pivotal Phase III and help improve lives of glaucoma patients. Welcome Mr. Bender.

Bender先生加入MediPrint Ophthalmics是及时的，因为该公司将其青光眼药物的领先产品推进到关键的III期，并有助于改善青光眼患者的生活。欢迎Bender先生。

MediPrint Ophthalmics stands at the forefront of Ophthalmic innovation as a clinical-stage platform technology company revolutionizing ocular drug delivery. With a steadfast commitment to enhancing vision, our flagship product involves proprietary 3D printing of bimatoprost drug onto contact lenses, delivering sustained relief to patients battling Glaucoma or Ocular Hypertension.

MediPrint Ophthalmics作为一家革新眼部药物输送的临床平台技术公司，站在眼科创新的前沿。凭借对增强视力的坚定承诺，我们的旗舰产品涉及将比马前列素药物专有3D打印到隐形眼镜上，为患有青光眼或高眼压的患者提供持续缓解。

Affecting over 100 million individuals globally and more than 8 million in the US alone, Glaucoma and Ocular Hypertension are primarily treated by ophthalmic drops representing significant unmet needs. MediPrint has successfully completed its Phase II clinical study. Our robust pipeline is focused on products designed to enhance comfort, alleviate dry eye, and combat various ocular diseases.

青光眼和高眼压症主要通过滴眼液治疗，全球有1亿多人受到影响，仅在美国就有800多万人受到影响，这些滴眼液代表了严重的未满足需求。MediPrint已成功完成其II期临床研究。我们强大的产品线专注于提高舒适度、缓解干眼症和对抗各种眼部疾病的产品。

Based in San Diego, California, MediPrint is not just pioneering change; we are defining the future of ocular drug delivery..

总部位于加利福尼亚州圣地亚哥的MediPrint不仅是开创性的变革；我们正在定义眼部药物输送的未来。。